Over time, researchers’ interest in gut health has grown. Thus far, researchers have connected it to inflammation, digestion, and even mental health.
There may be a close relationship between gut health and the brain, according to new studies. University College London researchers investigated the relationship between Parkinson’s illness and intestinal health.
They discovered a link between the risk of Parkinson’s disease and the gut microbiome. The results imply that changes in gut bacteria may be a crucial early indicator to monitor in comprehending and diagnosing the illness, albeit additional research is required.
What is the connection between Parkinson’s disease and gut health?
Approximately 1.1 million Americans suffer with Parkinson’s disease, a neurological disorder. The neurodegenerative illness can result in dementia and impair movement.
The illness worsens with time and there is no cure, however there are therapies to assist control symptoms. Because of this, a lot of researchers are concentrating on finding early warning indicators and novel preventative strategies.
Three participant types’ gut microbiota data were examined by the researchers:
- Parkinson’s disease patients (271)
- individuals without symptoms who have the genetic risk factor GBA1 (43)
- controls in good health (150)
In order to identify various gut bacteria and determine how frequent or uncommon these germs are in each individual, they collected feces samples. This made it easier to comprehend the general balance of the gut and identify trends associated with the development or risk of disease.
The individuals’ diet, cognitive abilities, motor and non-motor complaints, and other health aspects were also evaluated by the researchers.
Changes in the gut could be a sign of illness
The researchers found patterns linked to illness risk and progression by integrating clinical data with microbiome analysis.
When comparing the gut microbiomes of people with Parkinson’s disease to those of healthy people, the researchers discovered clear differences.
When the Parkinson’s disease group was compared to the control group, the researchers found that about 25% of the gut microbiome had changed significantly.
The researchers found a correlation between the severity of Parkinson’s disease and the degree of microbiome alterations. The gut microbiota of those with more advanced Parkinson’s disease was more disrupted.
The researchers categorized a portion of the GBA1 group as “prodromal,” or the pre-diagnostic stage of Parkinson’s disease, based on non-motor symptoms (such as autonomic dysfunction and REM Sleep Behavior Disorder).
Additionally, they discovered that this subgroup had a higher “abundance” of these microbe species than both the GBA1 group members without non-motor symptoms and the healthy group.
These results led the researchers to speculate that alterations in the stomach might start years before symptoms appear. They believe that these patterns may eventually function as an early indicator of the illness.
All things considered, the study might be a step toward developing a method for early Parkinson’s disease detection and the application of both preventative and therapeutic approaches.
Will the treatment of Parkinson’s change as a result?
The results were discussed with Medical News Today by Julie Pilitsis, MD, PhD, Chair of Neurosurgery at the University of Arizona Tucson and Physician Executive in the Functional Neurosurgery program at Banner University Medical Center. Pilitsis mentioned the study’s strengths.
According to Pilitsis, “a major strength of this study is that these patterns held up across the globe.” “The researchers discovered similar bacterial alterations in Parkinson’s patients everywhere when they compared their findings with data from studies in the United States, South Korea, and Turkey.”
According to Pilitsis, individuals with the Parkinson’s genetic risk factor may experience unwarranted fear as a result of the findings.
According to her, “the majority of people do not develop Parkinson’s disease because just 10% of patients with GBA1 variations develop [Parkinson’s disease] by age 60 and 19% by age 80.”
According to Pilitsis, “additional research is needed before these findings can be applied in patient care for Parkinson’s disease, especially long-term research,” and the results will not affect how medicine is currently managed.